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Associations between human papillomavirus
and history of cancer among U.S. adults in the
National Health and Nutrition Examination
Survey (2003–2010)
B Liu1 and E Taioli*,1
1Department of Population Health and the Feinstein Institute, Hofstra North Shore-LIJ School of Medicine, 175 Community Drive,
Rm 203, Great Neck, NY 11021, USA
Background: Human papillomavirus (HPV) is an infectious agent that has been associated with human cancer. We have updated
the U.S. population sero-prevalence using a large National Health and Nutrition Examination Survey (NHANES) sample of adults
from 2003 to 2010, and have analysed the associations between HPV seropositivity and self-reported history of cancer.
Methods: Four cross-sectional cycles (2003–2004, 2005–2006, 2007–2008, and 2009–2010) were used, for a total of 12 759
participants who had both cancer history and HPV serum information.
Results: The sero-prevalences of HPV types 6, 11, 16, and 18 were 15.0%, 4.8%, 11.5%, and 4.1%, respectively. Females had
significantly higher HPV prevalence than males (Po0.05) for all subtypes. Positive associations between HPV 16/18 seropositivity
and lifetime history of any cancer (adjusted odds ratio-ORadj¼ 1.68; 95% CI: 1.35, 2.01), history of any of eight selected cancers
(ORadj¼ 2.63; 95% CI: 1.78, 3.90), lung cancer (ORadj¼ 5.14; 95% CI: 1.29, 20.44), and cervical cancer (ORadj¼ 2.55; 95% CI: 1.63,
3.98) were observed.
Conclusions: The finding of significant associations between HPV 16/18 seropositivity and lifetime history of cancer adds
epidemiological evidence to the carcinogenicity potential of HPV 16 and 18 in other tissues. With increasing coverage of the HPV
vaccine in the U.S., future NHANES data and sample collection may allow further detailed evaluation of the population impact of
the HPV vaccination on cancer prevention.
Human papillomavirus (HPV) is an infectious agent that has been
associated with human cancer (zur Hausen, 1996). There are more
than 100 HPV subtypes, some of which, like HPV 16 or HPV 18,
were identified as oncogenic or high-risk types after the
epidemiologic observation that not all the cervical lesions evolve
into cervical cancer (zur Hausen, 1986, 2002). HPV 16 and 18
have been associated with cervical and anogenital cancers
(zur Hausen, 1996), and in more recent years to other cancer
types, such as lung (Syrjanen, 2012; Ragin et al, 2014), head and
neck (Gillison et al, 2000), and prostate cancers (Dillner et al, 1998;
Whitaker et al, 2013).
Overall HPV sero-prevalence in the United States has been
described using the 2003–2004 National Health and Nutrition
Examination Survey (NHANES) data (Stone et al, 2002; Markowitz
et al, 2009), or has been ascertained using cervical swabs among
women, in an attempt to assess the effect of HPV vaccination
(Markowitz et al, 2013); the population sero-prevalence of HPV 16
alone has also been published (Stone et al, 2002). We are updating
the population sero-prevalence using a large NHANES sample of
adults from 2003 to 2010.
Given that sero-prevalence of HPV 16 or 18 provides
reasonable estimates of cumulative exposure (Chua et al, 1996; af
*Correspondence: Dr E Taioli; E-mail: Etaioli@NSHS.edu
Received 16 April 2014; revised 27 June 2014; accepted 1 July 2014; published online 24 July 2014
& 2014 Cancer Research UK. All rights reserved 0007 – 0920/14
FULL PAPER
Keywords: HPV; carcinogenesis; epidemiology; NHANES
British Journal of Cancer (2014) 111, 1448–1453 | doi: 10.1038/bjc.2014.414
1448 www.bjcancer.com |DOI:10.1038/bjc.2014.414
Geijersstam et al, 1998; Markowitz et al, 2009, 2013), and the
implication of HPV as an aetiologic risk factor for some major
human cancers, we are also analysing the associations between
HPV seropositivity and self-reported history of cancer. We
hypothesised that seropositivity of HPV 16 or 18 is associated
with a higher frequency of personal history of cancer compared
with seronegativity.
MATERIALS AND METHODS
Study population and design. The NHANES surveys were
conducted by the U.S. National Center for Health Statistics
(NCHS) of the Centers for Disease Control and Prevention (CDC)
to assess the health and nutritional status of adults and children in
the U.S. The NHANES study protocol has been described
previously in detail by by CDC (Zipf et al, 2013). In brief, civilians,
non-institutionalized persons in the U.S. aged 2 months or older
were eligible to participate. They were selected through a stratified,
multi-stage, probability-cluster design. The survey’s components
were administered in homes and in mobile examination centres,
and also provided national reference data for biological markers,
anthropometric measures, as well as demographic and socio-
economic status data.
Four cross-sectional cycles (2003–2004, 2005–2006, 2007–2008,
and 2009–2010) were used and combined using NCHS recom-
mendations (NCHS, 2008, 2013). Of the initial 41 156 participants,
those who lacked information on either only HPV serum
(n¼ 9223), only on history of cancer (n¼ 1562), or both
(n¼ 17 455) were excluded. Among the remaining 12 916 partici-
pants who had both cancer and HPV serum information, 45 and
112 participants from the 2007–2008 and 2009–2010 survey cycles,
respectively, received HPV vaccination, and these 157 people were
also excluded. The final population consisted of 12 759 adults aged
18–59 years. The NHANES protocol was developed and reviewed
in compliance with the policies for protection of human research
subjects developed by the U.S. Department of Health and Human
Services (Zipf et al, 2013). The Institutional Review Board of the
Feinstein Institute for Medical Research determined that this study
is IRB exempt.
History of cancer. Lifetime cancer history was defined based on a
positive answer to the question in the medical condition
questionnaire: ‘Have you ever been told by a doctor or other
health professional that you had cancer or a malignancy of any
kind?’.
Eight specific cancers that were potentially linked to HPV were
identified based on positive answers to the subsequent questions
‘What kind of cancer?’; they were cervix, oesophagus, larynx/
windpipe, lung, mouth/tongue/lip, ovary, prostate, and rectum. No
information on vulvar, anal, penile, or vaginal cancers was
collected. An additional dichotomised cancer variable (eight
selected cancer) was created which included a positive answer to
having had any of those eight cancers.
Serum HPV. All NHANES participants aged 18–59 years were
eligible for serologic testing. Serum samples were analysed using
the Luminex platform to simultaneously assay antibodies to HPV
6, 11, 16, and 18, and were detected by a multiplexed, competitive
immunoassay by displacement of fluorescently tagged neutralising
monoclonal antibody from virus-like particles (VLP)-coated
microspheres (Opalka et al, 2003; Dias et al, 2005). Dichotomized
serostatus (positive or negative) were defined by NHANES based
on cutoff values (mMUml 1): X20, X16, X20, and X24 for
types 6, 11, 16, and 18, respectively. For analytic purposes, three
additional HPV variables were created: positivity to any of the four
HPV types (HPV any four), HPV 6/11, and HPV 16/18, with the
later two representing low- and high-risk HPV types, respectively.
Other covariates. The associations between cancer and HPV
serostatus were adjusted for the following a priori possible
confounders: sex, age, race, education, poverty income ratio
(PIR), body mass index (BMI), smoking status, and alcohol use.
Age was categorised into four groups: 18–29, 30–39, 40–49, and
50–59 years. Race included three categories: non-Hispanic white,
non-Hispanic black, and other, where other consisted of mainly
Mexican-American and other Hispanic, as well as other races
(including multi-racial subjects). The latter category represented
approximately 3–6% of the total sample in each survey cycle.
Education was grouped into three categories: greater, equal, or less
than high school level, where high school was defined as having 12
years of primary and secondary school. PIR in NHANES was
calculated by dividing family income by the poverty level issued by
the Department of Health and Human Services, which is specific to
family size, the appropriate year and state. In this study, PIR was
grouped into three categories: o1, 1pPIRpmedian, 4median,
where medians (B2.3–2.7) were calculated based on the PIRX1
for each survey cycle. BMI was grouped into two categories based
on the cutoff value of 25 kgm 2, where BMI X25 kgm 2
indicates overweight and obese weight status based on commonly
used health guidelines (CDC; NIH). Dichotomised smoking status
was based on positive answers to the question, ‘Have you smoked
at least 100 cigarettes in your entire life?’. Dichotomised alcohol
use was based on positive answers to the question, ‘Have you had
at least 12 alcohol drinks per 1 year?’.
Statistical methods. The sero-prevalences of HPV types were
calculated for the overall data, as well as stratified by sex, race, age
groups, survey cycles, and cancer status. The HPV–cancer
associations were tested using logistical regression, and models
were fit with one cancer variable at a time. The crude model was fit
with each of the seven HPV indicators as the only predictor (one at
a time), to obtain a preliminary understanding of the HPV–cancer
associations. The adjusted models were run with HPV 16/18 only,
as 16 and 18 are high-risk viral subtypes. Models run on the whole-
data set consisted of both males and females, except for cervical
cancer and ovarian cancer, which were run on a female-only data
set, and prostate cancer, which was run on a male-only data set.
Statistical analyses were performed using SAS software (version
9.3, Cary, NC, USA) and sampling weights were applied to account
for the complex sampling NHANES design according to NHANES
guidelines (NCHS, 2013).
RESULTS
Table 1 lists the weighted characteristics of the participants 18–59
years of age from NHANES 2003–2010 included in this study
(n¼ 12 759). The weighted mean age (±s.e.) of the participants
was 39.6±0.16 years. Half of the participants were females and
about 66% of the total population was overweight or obese
(BMIX25 kgm 2). Non-Hispanic whites accounted for 68% of
the total population; 11.5% were non-Hispanic blacks. Approxi-
mately 19% of the participants were from families with income
below the poverty level (PIRo1), and 17% of the participants had
lower than high school education. Non-smokers and non-drinkers
accounted for 52% and 22% of the total population, respectively.
The prevalence (±s.e.) of lifetime history of cancer, any of the
eight selected cancers, and cervical cancer were 4.88±0.26%,
1.44±0.16%, and 0.97±0.12%, respectively. The prevalence of the
other cancer types was below 0.13%.
The sero-prevalences of HPV types 6, 11, 16, and 18 were 15.0%,
4.8%, 11.5%, and 4.1%, respectively, and remained relatively stable
across the four survey cycles between 2003 and 2010: prevalence
ranges were 12.8–17.2%, 4.4–5.4%, 11.1–11.8%, and 3.7–4.6% for
HPV types 6, 11, 16, and 18, respectively. Females had significantly
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higher HPV prevalence than males (Po0.05) for all subtypes
(Figure 1). The sero-prevalence of HPV 6/11 was 17.2% overall,
and was 24.9% and 9.5% among females and males, respectively.
The sero-prevalence of HPV 16/18 was 14.0% overall, and was
21.4% and 6.7% among females and males, respectively. The sero-
prevalence of any of the four HPV types was 25.5% overall, and
was 36.6% and 14.4% among females and males, respectively. The
sero-prevalences of the HPV types also varied by age (Figure 2)
and by race/ethnicity (Figure 3), with elevated sero-prevalences
seen among those aged 30–39 years and among blacks.
Compared with non-cancer cases, sero-prevalences of HPV 16/
18 were generally higher among participants with a lifetime history
of cancer (Table 2), for history of any of the eight selected cancers,
cervical, lung, and ovarian cancer. In general, the prevalence of
HPV 16/18 among participants with a history of cancer was 1.6–3
times higher than the overall HPV 16/18 prevalence (14%).
Uncertainties of the estimates for history of other cancers are large,
likely because of the limited number of cancer cases (no5) and/or
large standard errors (430%).
Results from the crude logistic models showed significant
positive associations between HPV 16/18 serum positivity and the
following variables: lifetime history of cancer, history of any of the
eight selected cancers, cervical, and lung cancers. HPV 16/18
serum positivity was not significantly associated with larynx/
windpipe, mouth/tongue/lip, ovarian, and prostate cancers (data
not shown). Due to the small sample size of oesophageal (two
cases) and rectal cancer (one case) cases, no reliable results were
found as the convergence criteria required to run the model were
not met.
Multivariable analysis. For the study population as a whole,
positive associations between HPV 16/18 seropositivity and
lifetime history of any cancer (adjusted odds ratio-ORadj¼ 1.68;
95% CI: 1.35, 2.01), history of any of the eight selected cancers
(ORadj¼ 2.63; 95% CI: 1.78, 3.90), and lung cancer (ORadj¼ 5.14;
95% CI: 1.29, 20.44) were observed (Table 3). Age and sex were two
common significant covariates in the adjusted models for these
three types of cancer. Among females, similar positive associations
were found between HPV 16/18 seropositivity and history of
cancer (ORadj¼ 1.57; 95% CI: 1.22, 2.01), history of any of the
eight selected cancers (ORadj¼ 2.57; 95% CI: 1.64, 4.03), and lung
cancer (ORadj¼ 5.04; 95% CI: 1.34, 18.92). In addition, HPV 16/18
was found to be a significant predictor for cervical cancer
(ORadj¼ 2.55; 95% CI: 1.63, 3.98). Among males, HPV 16/18
positivity was borderline significantly associated only with lifetime
history of cancer (ORadj¼ 1.81; 95% CI: 0.98, 3.33).
DISCUSSION
We examined the associations between HPV serum infection and
history of cancer among a large population sample of U.S. adults
aged 18–59 years. HPV infection with two of the high-risk strains
(HPV 16 or HPV 18) was associated with lifetime history of cancer,
history of eight selected cancers, and lung cancer in the study
population as a whole and among females, as well as with cervical
Table 1. Weighted characteristics of the study population—National
Health and Nutrition Examination Survey (NHANES) 2003–2010
Characteristic Number Weighted percent s.e.
Sex
Males 6180 49.98 0.39
Females 6579 50.02 0.39
Age
18–29 years 3341 23.72 0.58
30–39 years 3264 24.66 0.56
40–49 years 3331 27.66 0.55
50–59 years 2823 23.96 0.64
Race
White 5853 67.99 1.77
Black 2602 11.52 0.88
Others 4304 20.49 1.39
Education
ohigh school 3231 16.71 0.66
¼ high school 3041 24.03 0.61
4high school 6478 59.26 0.94
Poverty income ratio
o1 3444 18.68 0.67
1pPIRpmedian 4060 26.46 0.71
4median 5255 54.86 0.97
Body mass index
X25 kgm 2 8743 65.95 0.69
Smoking
Yes 5904 48.11 0.86
Alcohol use
Yes 8690 78.01 0.84
Lifetime cancer
Yes 508 4.88 0.26
Selected eight cancers
Yes 177 1.44 0.16
Cervical cancer
Yes 124 0.97 0.12
Oesophageal cancer
Yes 2 0.02 0.02
Larynx/windpipe cancer
Yes 2 0.04 0.03
Lung cancer
Yes 11 0.09 0.03
Mouth/tongue/lip cancer
Yes 5 0.05 0.02
Ovarian cancer
Yes 20 0.13 0.04
Table 1. ( Continued )
Characteristic Number Weighted percent s.e.
Prostate cancer
Yes 14 0.13 0.05
Rectal cancer
Yes 1 0.01 0.01
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cancer among females. These associations remained significant
after adjusting for some possible confounders, such as age, race,
smoking, and drinking status.
The finding of significant positive associations between HPV
16/18 seropositivity and cervical cancer is not surprising, given the
well-established aetiologic role that HPV 16 and 18 play in the
development of cervical cancer (Clifford et al, 2003; Bosch et al,
2008). National surveillance data have shown higher incidence of
cervical cancer among blacks (Watson et al, 2008); similarly, in the
present analysis, non-Hispanic blacks had the highest HPV 16/18
seropositivity. A similar trend has also been reported in a previous
analysis of NHANES (2003–2004) participants aged 14–59
(Markowitz et al, 2009). However, our data suggest that race was
not a significant predictor of the association between HPV
seropositivity and history of cervical cancer in the multivariable
model.
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Figure 1. Weighted sero-prevalences (±2 s.e.) of human
papillomavirus (HPV) types 6, 11, 16, and 18 according to sex—
NHANES 2003–2010.
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Figure 2. Weighted sero-prevalences (±2 s.e.) of human
papillomavirus (HPV) types 6, 11, 16, and 18 according to age
(years)—NHANES 2003–2010.
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Figure 3. Weighted sero-prevalences (±2 s.e.) of human
papillomavirus (HPV) types 6, 11, 16, and 18 according to race/
ethnicity—NHANES 2003–2010.
Table 2. Prevalence of seropositivity of human papillomavirus (HPV) types
16 or 18 according to cancer history (National Health and Nutrition
Examination Survey (NHANES) 2003–2010)
Variable HPV 16/18 Number
Weighted
percent HPV
16/18 þ s.e.
Lifetime history
Cancer þ / 130/378 22.8 1.8
Non-cancer þ / 1757/10 494 13.6 0.3
Eight selected
Cancer þ / 66/111 37.6 4.1
Non-cancer þ /¼ 1821/10 761 13.7 0.3
Cervix
Cancer þ /- 52/72 42.5 5.1
Non-cancer þ /- 1835/10 800 13.7 0.3
Oesophagus
Cancer þ / 0/2
Non-cancer þ / 1887/10 870 14.0 0.3
Larynx
Cancer þ / 1/1 49.9 35.4
Non-cancer þ / 1886/10 871 14.0 0.3
Lung
Cancer þ / 5/6 42.4 18.4
Non-cancer þ / 1882/10 866 14.0 0.3
Mouth
Cancer þ / 1/4 30.6 24.5
Non-cancer þ / 1886/10 868 14.0 0.3
Ovary
Cancer þ / 6/14 25.5 9.2
Non-cancer þ / 1881/10 858 14.0 0.3
Prostate
Cancer þ / 1/13 10.3 10.0
Non-cancer þ 1886/10 859 14.0 0.3
Rectum
Cancer þ / 1/0 100.0 0.0
Non-cancer þ / 1886/10 872 14.0 0.3
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The fact that the association between history of cervical cancer
and HPV seropostivity is weak could be explained in part by
cervical cancer aggressiveness, patterns of cervix cancer screening
and follow-up/treatment services (Watson et al, 2008), as well as
heterogeneity and misclassification in cervical cancer, since pre-
cancerous cervical lesions discovered through routine screenings
are often perceived by women as ‘cancer’.
The link between HPV infection and lung cancer is still debated.
The present analysis shows a significant association between a
history of lung cancer and HPV 16/18 serological positivity in
females. This association is in contrast with results from a large
longitudinal nested case-control study of Finnish women (Simen-
Kapeu et al, 2010), which reported no increased risk of lung cancer
with serum HPV 16/18 infection. The discrepancies in study design
and the method used for the estimate of smoking (self-reported vs
cotinine level) may have contributed to the differences observed
between the present study and the Finnish study. A recent pooled
analysis suggested that viral integration in the DNA, a sign of
carcinogenicity, was almost exclusively present among females
compared with males, but in a small sample of lung cancer cases
(Ragin et al, 2014). Other studies using HPV DNA have suggested
a high prevalence of HPV in lung cancer tumours compared with
normal tissues (Klein et al, 2009; Srinivasan et al, 2009; Syrjanen,
2012; Ragin et al, 2014). In vitro studies also showed that
benzo[a]pyrene, a major carcinogen in cigarette smoke, enhances
virion syntheses of HPV 16 and 18 (Alam et al, 2008). However, a
recent study (Anantharaman et al, 2014) found no association
between HPV antibodies or HPV DNA and lung cancer.
The significant associations between HPV 16/18 seropositivity
and a comprehensive variable including eight selected cancer types
(cervix, oesophagus, larynx/windpipe, lung, mouth/tongue/lip,
ovary, prostate, and rectum) supports the notion that those subjects
with HPV 16/18 seropositivity may be at higher risk for these
cancers. While estimates for each of these specific cancer types could
not be calculated in this data set due to small sample sizes of
captured cancer cases, our result is consistent with those from cancer
type-specific studies. For instance, research based on HPV DNA
data has also shown increases in the population level incidence of
HPV-positive oropharyngeal cancers in the U.S. (Chaturvedi et al,
2011), Sweden (Nasman et al, 2009), and Canada (Nichols et al,
2013). A wide range of elevated HPV prevalence has also been
reported, albeit with large variations, for cancer tissues such as
ovarian (15.5%, ranged¼ 0–66.7%; (Svahn et al, 2014)), oesophageal
(30.9%; (Syrjanen & Syrjanen, 2013)), as well as prostate cancers
(HPV 16/18 sero-prevalence: 0.04–10.3%; (Dillner et al, 1998)).
The finding of significant associations between HPV 16/18
seropositivity and lifetime history of cancer adds epidemiological
evidence to the carcinogenicity potential of HPV 16 and 18 on other
tissues in addition to anogenital and oropharyngeal sites. The
observed HPV–cancer association was also consistent with the high
HPV 16/18 sero-prevalence seen in this study among participants
with a history of cancer in comparison with those without any cancer.
The results of this study represent one of the most comprehensive
pictures of U.S. population-based HPV infection in the context of
cancer. The data consisted of four NHANES surveys between 2003
and 2010. In addition, both males and females were included in the
analysis. A major limitation is the cross-sectional nature of the
survey, which prevented the examination of temporal associations
between HPV infection and cancers, and the fact that only
antibodies to L1, the HPV structural proteins, were assessed in
NHANES. It was not possible to determine the time frame between
HPV testing and cancer occurrence. It was also not clear whether the
observed seropositivity represented recent, latent, or reactivation of
infection, and to what extent the natural history of seroreactivity
differed between controls and cancer cases, whose immune response
may be compromised due to cancer treatment. While HPV capsid
antibody levels are stable during several years of follow-up (af
Geijersstam et al, 1998) and HPV 16/18 had relatively persistent
antibody responses, although with some variations (Carter et al,
2000; Ho et al, 2004), the use of HPV seropositivity in aetiological
cancer studies is still emerging and need to be confirmed in tumour
tissues. Other limitations include the rudimentary assessment of
smoking history which is the main risk factor for many cancer sites,
and the omission of other potential confounders such as lifetime
number of sex partners, which has been shown to be associated with
a increased risk of HPV infection (Markowitz et al, 2009) and is
likely associated with smoking status as well. The relatively small
number of cases for some cancers, and the fact that the outcomes
were based on self-reported history, and for selected common
cancers only, may have contributed to the wide error bars and
confidence intervals observed. In addition, for some lethal cancer
types, such as ovarian or lung cancer, a personal history of cancer
likely captures only those who survived, thus introducing a
survivorship bias. This bias, together with recall bias, may have
affected the relative magnitude of the associations observed; for
example, the association between HPV infection and history of lung
cancer is unusually stronger than the association HPV–cervical
cancer. It is possible that lung cancer survival differs according to the
presence of HPV infection, as is well established for head and neck
cancer, thus selecting for survival only those cases that are HPV
positive.
However, our results suggest an association in the U.S. general
population between seropositivity of high-risk HPV types (16/18)
and lifetime history of cancer, cancer of the cervix and lung, and
history of any of eight cancers that were selected because of their
potential association with HPV. Further investigations into these
associations using tumour tissues, a larger sample size, and a
prospective design are warranted. With increasing coverage of
HPV vaccine in the U.S., future NHANES data and sample
collection may allow further detailed evaluation of the HPV–cancer
relationship, as well as the population impact of HPV vaccination
on cancer prevention.
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